A Phase 1/2 interventional study of VAY736 lower dose and VAY736 higher dose in Primary Sjögren's Syndrome, sponsored by Novartis Pharmaceuticals. Withdrawn. Per ClinicalTrials.gov, last updated 2017-04-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.
Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 1/2, and was the 2nd registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 4
First in 2014; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 240 across the 14 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Sjogren's Syndrome by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method is a valid method to assess B cells in salivary glands of pSS patients. In Part 1 and Part 2 no IMP will be applied to the subjects. In Part 3, pSS patients (n=12) will receive the IMP, VAY736. Posted information will be focused on Part 3.
The overarching purpose of this study is to test a new drug (VAY736) for the treatment of pSS. In pSS, the salivary glands (the glands that produce saliva) and other organs are affected by inflammation. A certain type of white blood cells called B cells prominently infiltrate the salivary glands in pSS, whereas they are not present in healthy salivary glands. Scientific evidence suggests that B cells may be involved in the disease process in pSS and that eliminating B cells may benefit patients with pSS. This study will test a new imaging method and a new treatment for pSS. Both the imaging method and the treatment are specific for B cells.
Part 1 and 3:
Inclusion Criteria:
Exclusion Criteria:
Part 2
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
Drug: VAY736 lower dose
12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
Drug: VAY736 higher dose
Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging
Part 1: PET/CT imaging of pSS major salivary gland 3, 6 and 9 days after i.v. injection with \[Zr- 89\]rituximab
Time frame: Part 1: 4 weeks
Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab
Part 2: PET/CT imaging of healthy volunteers' major salivary gland, cervical lymph nodes and spleen on optimal time point after i.v. injection with \[Zr-89\]-rituximab (e.g. 3 days after injection)
Time frame: Part 2: 4 weeks
Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging
Part 3: PET/CT imaging of pSS tissues on optimal time point after i.v. injection with \[Zr-89\]-rituximab, at baseline and 12 weeks after the start of VAY736 treatment
Time frame: Part 3: 12 weeks
Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments
AEs, vital signs, ECGs, safety laboratory parameters (Hematology, Biochmistry, Urinalysis)
Time frame: 12 weeks
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - Area under the curve (AUC)
Time frame: 12 weeks
To assess the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - Trough concentrations after multiple dose
Time frame: 12 weeks
Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS
Multiple s.c. dose VAY736 PD parameter - depletion of B cells
Time frame: 12 weeks
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements
Time frame: 12 weeks
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess salivary glands size and echostructure by ultrasound
Time frame: 12 weeks
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)
Time frame: 12 weeks
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess lacrimal gland function by Schirmer's test
Time frame: 12 weeks
To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity
Assess the change in the EULAR Sjögren'sSyndrome Disease Activity Index (ESSDAI).
Time frame: 12 weeks
To evaluate the effect of on self-reported outcomes in pSS patients
Multidimensional Fatigue Inventory (MFI-20); the short form 36 health Survey (SF-36); EULAR Sjögren's Syndorm Patient Reported Intensity (ESSPRI)
Time frame: 12 weeks
To evaluate the change in the physician global assessment of patients's overall disease activity
Physician's visual anaglog scale (VAS)
Time frame: 12 weeks
To evaluate the change in the patients global assessment of their disease activity
Patient's visual analogue scale (VAS)
Time frame: 12 weeks
To assess the immunogenicity of VAY736
Anti-VAY736 antibodies
Time frame: 12 weeks
To assess the immunogenicity of a micodose of rituximab
Anti-rituximab antibodies
Time frame: 25 weeks
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - Cmax
Time frame: 12 weeks
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - tmax
Time frame: 12 weeks
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - half live (t1/2)
Time frame: 12 weeks
No study locations are listed for this record.
The record gives a start of Dec 2015, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab